Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · BETA

Beta Drugs Ltd

HealthcarePharmaceuticals & Biotechnology₹1827 cr market cap
₹1764.20 ▼ -2.11% today As of 19 Nov 2026
52-week low ₹1030.3052-week high ₹2668.30

-32.5% from the 52-week high · +74.9% above the low

Beta Drugs Ltd. engages in the manufacturing and trading of pharmaceuticals. The company is headquartered in Panchkula, Haryana. The company went IPO on 2017-10-12. The firm offers a range of oncology products including tablets, capsules and injections. The firm offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, brain, bone, lung, mouth, head and neck, prostate, leukemia, lymphoma and supportive cancer and others. The Company’s oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ADTHAL, Triodelta and others.

The short version. Return on equity was 17.0% in Mar 2026. Promoter holding was 58.91% in Sep 2026, down 7.82 points over 8 quarters.

1 · The price

How has the stock traded?

Beta Drugs Ltd trades 32.5% below its 52-week high and 74.9% above its 52-week low.

Change over period: —

1M+4.8%
3M-24.9%
6M+48.3%
1Y—

2 · The business

Is it growing?

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025
Revenue1371269487
Net profit201799
Net margin %14.613.79.69.8
EPS (₹)18.015.498.938.44

Annual

FY2026FY2025
Revenue385362
Net profit4142
Net margin %10.811.7
EPS (₹)40.9242.02

3 · The quality

How well does it turn capital into profit?

Return on equity was 17.0% in Mar 2026; debt to equity is 0.60.

Profitability · 2 years

Returns and margins

Mar 2026Mar 2025
Return on equity %17.021.5
Return on capital %18.019.2
EBITDA margin %21.920.7
Net margin %10.511.5

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.60
Interest cover4.6x
Current ratio3.10
P/E ratio37.2

4 · The owners

Who holds it, and are they adding?

Promoter holding58.91%

Down 7.82 pts over 8 quarters.

Foreign institutions1.37%

Up 0.22 pts over 8 quarters.

Domestic institutions6.45%

Up 6.28 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter66.7366.7366.7366.7364.964.6359.158.91-7.82
FII1.150.90.90.91.141.161.021.37+0.22
DII0.170.170.260.291.92.156.236.45+6.28
Public31.9532.232.1132.0732.0732.0633.6533.27+1.32

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for Beta Drugs Ltd are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about Beta Drugs Ltd

What is the Beta Drugs Ltd share price?

Beta Drugs Ltd (BETA) last closed at ₹1,764.20, down 2.11% on the day. Its 52-week range is ₹1,030.30 to ₹2,668.30.

What is the market cap of Beta Drugs Ltd?

Beta Drugs Ltd has a market capitalisation of about ₹1,827 crore. Its price-to-earnings ratio is 37.2.

How are Beta Drugs Ltd's latest results?

Return on equity was 17.0% in Mar 2026. Promoter holding was 58.91% in Sep 2026, down 7.82 points over 8 quarters.

Who owns Beta Drugs Ltd?

As of Sep 2026, shareholding was: Promoter 58.91%, FII 1.37%, DII 6.45%, Public 33.27%.

How many mutual funds hold Beta Drugs Ltd?

0 mutual fund schemes held Beta Drugs Ltd in October 2026. That compares with 0 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.